Barclays reiterated an "overweight" rating on this Biotech company and raised its conviction in the drugmaker's Phase 3 myositis trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE